Dr. Reddy's Laboratories faces a deteriorating fundamental picture with declining revenue of 12% year-over-year, two consecutive earnings misses, a death cross blocking entry, and the stock already priced above analyst targets — making the current setup one of the weakest risk-reward profiles in the healthcare sector despite reasonable absolute valuation multiples.
Thesis pillars
- Revenue Decline And Miss Pattern→Stable
- Death Cross And Negative Asymmetry→Stable
- Extreme Put Call Ratio↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $12.75 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and... Read more
Sell if holding. Analyst target reached at $12.75 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 59. Score 4.5/10, moderate confidence.
Passes 6/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-10-15Recent Developments — Dr. Reddy's Laboratories Ltd
Latest news
- NEWS A Look at Dr Reddy's Laboratories Ltd (RDY) After 9.4% Decline -- GF Value $14.70 vs Price $11.38 - GuruFocus — GuruFocus negative
- NEWS Why Is Dr. Reddy's Stock Sinking Wednesday? - Dr Reddy's Laboratories (NYSE:RDY) - Benzinga — Benzinga negative
- NEWS Dr. Reddy's Laboratories (RDY) Stock Falls on Q4 2026 Earnings - Quiver Quantitative — Quiver Quantitative negative
- NEWS Dr. Reddy's Laboratories Q1 Earnings Call Highlights - Yahoo Finance — Yahoo Finance neutral
- NEWS Dr. Reddy's stock reflects steady 2026 profit growth - Ad-hoc-news.de — Ad-hoc-news.de positive
Generated 2026-10-15T11:52:21Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -5.6% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $12.75 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 59. Prior stop was $12.13. Score 4.5/10, moderate confidence.
Take-profit target: $14.66 (-5.7% upside). Prior stop was $12.13. Stop-loss: $12.13.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3); Consecutive earnings misses (2).
Dr. Reddy's Laboratories Ltd trades at a P/E of 29.0 (forward 19.9). TrendMatrix value score: 6.3/10. Verdict: Sell.
45 analysts cover RDY with a consensus score of 2.8/5. Average price target: $14.
What does Dr. Reddy's Laboratories Ltd do?Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company...
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.